242 related articles for article (PubMed ID: 38187402)
1. Ovarian cancer treatment and natural killer cell-based immunotherapy.
Fan Z; Han D; Fan X; Zhao L
Front Immunol; 2023; 14():1308143. PubMed ID: 38187402
[TBL] [Abstract][Full Text] [Related]
2. Harnessing natural killer cells for the treatment of ovarian cancer.
Hoogstad-van Evert JS; Bekkers R; Ottevanger N; Jansen JH; Massuger L; Dolstra H
Gynecol Oncol; 2020 Jun; 157(3):810-816. PubMed ID: 32268953
[TBL] [Abstract][Full Text] [Related]
3. Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer.
Nersesian S; Glazebrook H; Toulany J; Grantham SR; Boudreau JE
Front Immunol; 2019; 10():1782. PubMed ID: 31456796
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo-expanded NK cells from blood and ascites of ovarian cancer patients are cytotoxic against autologous primary ovarian cancer cells.
Nham T; Poznanski SM; Fan IY; Shenouda MM; Chew MV; Lee AJ; Vahedi F; Karimi Y; Butcher M; Lee DA; Hirte H; Ashkar AA
Cancer Immunol Immunother; 2018 Apr; 67(4):575-587. PubMed ID: 29299659
[TBL] [Abstract][Full Text] [Related]
5. Monocytes and the 38kDa-antigen of mycobacterium tuberculosis modulate natural killer cell activity and their cytolysis directed against ovarian cancer cell lines.
Gottschalk N; Lang S; Kimmig R; Singh M; Brandau S
BMC Cancer; 2012 Oct; 12():451. PubMed ID: 23036052
[TBL] [Abstract][Full Text] [Related]
6. MiR-140-3p inhibits natural killer cytotoxicity to human ovarian cancer via targeting MAPK1.
Wang J; Zhu M; Zhou X; Wang T; Xi Y; Jing Z; Xi W
J Biosci; 2020; 45():. PubMed ID: 32385217
[TBL] [Abstract][Full Text] [Related]
7. Selenium-containing ruthenium complex synergizes with natural killer cells to enhance immunotherapy against prostate cancer via activating TRAIL/FasL signaling.
Lai H; Zeng D; Liu C; Zhang Q; Wang X; Chen T
Biomaterials; 2019 Oct; 219():119377. PubMed ID: 31374478
[TBL] [Abstract][Full Text] [Related]
8. Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy.
Gaggero S; Witt K; Carlsten M; Mitra S
Front Immunol; 2020; 11():621225. PubMed ID: 33584718
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy.
Fantini M; Arlen PM; Tsang KY
Front Immunol; 2023; 14():1275904. PubMed ID: 38077389
[TBL] [Abstract][Full Text] [Related]
10. PP4 inhibition sensitizes ovarian cancer to NK cell-mediated cytotoxicity via STAT1 activation and inflammatory signaling.
Raja R; Wu C; Bassoy EY; Rubino TE; Utagawa EC; Magtibay PM; Butler KA; Curtis M
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36564125
[TBL] [Abstract][Full Text] [Related]
11. Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer.
Kennedy PR; Felices M; Miller JS
Stem Cell Res Ther; 2022 Apr; 13(1):165. PubMed ID: 35414042
[TBL] [Abstract][Full Text] [Related]
12. Enhancing Natural Killer Cell-Mediated Cancer Immunotherapy by the Biological Macromolecule
Wu J; He B; Miao M; Han X; Dai H; Dou H; Li Y; Zhang X; Wang G
Pathol Oncol Res; 2022; 28():1610555. PubMed ID: 36110249
[TBL] [Abstract][Full Text] [Related]
13. Establishment, characterization, and successful adaptive therapy against human tumors of NKG cell, a new human NK cell line.
Cheng M; Ma J; Chen Y; Zhang J; Zhao W; Zhang J; Wei H; Ling B; Sun R; Tian Z
Cell Transplant; 2011; 20(11-12):1731-46. PubMed ID: 21669033
[TBL] [Abstract][Full Text] [Related]
14. IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34
Van der Meer JMR; Maas RJA; Guldevall K; Klarenaar K; de Jonge PKJD; Evert JSH; van der Waart AB; Cany J; Safrit JT; Lee JH; Wagena E; Friedl P; Önfelt B; Massuger LF; Schaap NPM; Jansen JH; Hobo W; Dolstra H
Cancer Immunol Immunother; 2021 May; 70(5):1305-1321. PubMed ID: 33140189
[TBL] [Abstract][Full Text] [Related]
15. Natural Killer Cells: the Missing Link in Effective Treatment for High-Grade Serous Ovarian Carcinoma.
Pugh-Toole M; Nicolela AP; Nersesian S; Leung BM; Boudreau JE
Curr Treat Options Oncol; 2022 Feb; 23(2):210-226. PubMed ID: 35192139
[TBL] [Abstract][Full Text] [Related]
16. Natural Killer T and Natural Killer Cell-Based Immunotherapy Strategies Targeting Cancer.
Iyoda T; Yamasaki S; Ueda S; Shimizu K; Fujii SI
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830717
[TBL] [Abstract][Full Text] [Related]
17. Stem-cell based, machine learning approach for optimizing natural killer cell-based personalized immunotherapy for high-grade ovarian cancer.
Esmail S; Danter WR
FEBS J; 2022 Feb; 289(4):985-998. PubMed ID: 34582617
[TBL] [Abstract][Full Text] [Related]
18. Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?
Ben-Shmuel A; Biber G; Barda-Saad M
Front Immunol; 2020; 11():275. PubMed ID: 32153582
[TBL] [Abstract][Full Text] [Related]
19. CD34
Van der Meer JMR; de Jonge PKJD; van der Waart AB; Geerlings AC; Moonen JP; Brummelman J; de Klein J; Vermeulen MC; Maas RJA; Schaap NPM; Hoogstad-van Evert JS; Ottevanger PB; Jansen JH; Hobo W; Dolstra H
Oncoimmunology; 2021; 10(1):1981049. PubMed ID: 34616589
[TBL] [Abstract][Full Text] [Related]
20. Driving natural killer cell-based cancer immunotherapy for cancer treatment: An arduous journey to promising ground.
Jiang D; Zhang J; Mao Z; Shi J; Ma P
Biomed Pharmacother; 2023 Sep; 165():115004. PubMed ID: 37352703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
